Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

Professor Yeo says if the neuronal sensors and brain pathways involved in appetite regulation are better understood, it may ...

A team of scientists has developed a new AI-based foundation model that can give insights into disease-causing mutations and ...

Dr. Thomas Hartung explains how AI and microphysiological systems (MPS) are changing drug safety testing. These ...

Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...

C3i became the first contract development and manufacturing organization (CDMO) for cell and gene therapies in Canada to ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Regenerative Medicine Advanced Therapy (RMAT) designation follows Phase Ib 36-month data Study demonstrated favorable safety profile and continued positive trends in assessed clinical outcome measures ...

Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory BoardDr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane ...

The U.S. Food and Drug Administration has approved vimseltinib for adult patients with a rare condition called tenosynovial ...

Three Australian companies will be presenting at Sharecafe's "Sip & Learn" webinar today—Nico Resources, Immutep, and ...

We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...